FATE THERAPEUTICS INC
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $1.3M | $1.4M | $1.7M | $1.9M | $1.6M | $1.9M | $3.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $24.4M | $24.7M | $25.4M | $25.8M | $27.4M | $29.1M | $33.6M | $34.7M |
| SG&A Expense | $8.8M | $9.6M | $10.7M | $10.6M | $11.4M | $13.8M | $15.3M | $20.8M |
| Operating Income | $-31.1M | $-33.0M | $-34.7M | $-34.7M | $-37.0M | $-41.3M | $-61.7M | $-52.4M |
| Operating Margin | -1,495.4% | -2,540.4% | -2,536.2% | -1,995.1% | -1,938.5% | -2,534.1% | -3,319.8% | -1,703.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-30.2M | $-31.2M | $-32.4M | $-32.3M | $-34.1M | $-37.6M | $-52.2M | $-47.7M |
| Net Margin | -1,448.6% | -2,402.8% | -2,364.8% | -1,852.4% | -1,786.6% | -2,309.5% | -2,803.9% | -1,551.0% |
| EPS (Basic) | $-0.25 | $-0.26 | $-0.27 | $-0.27 | $-0.29 | $-0.32 | $-0.44 | $-0.40 |
| EPS (Diluted) | $-0.25 | $-0.26 | $-0.27 | $-0.27 | $-0.29 | $-0.32 | $-0.44 | $-0.40 |
| Shares Outstanding (Basic) | 120.4M | 120.0M | 118.8M | 119.0M | 118.5M | 118.4M | 113.7M | 117.8M |
| Shares Outstanding (Diluted) | 120.4M | 120.0M | 118.8M | 119.0M | 118.5M | 118.4M | 113.7M | 117.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |